JHU's Neurofibromatosis Therapeutic Acceleration Program celebrated the 10th anniversary of its Francis S. Collins Scholars ...

A new study led by Indiana University School of Medicine researchers revealed a potential strategy to address neurobehavioral ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

The event, hosted by NF Network, included a 5K walk/run, a basket raffle and a time to share and spread awareness ...

The European Commission has approved EZMEKLY (mirdametinib) for treatment of symptomatic, inoperable plexiform neurofibromas ...

A new study led by Indiana University School of Medicine researchers revealed a potential strategy to address neurobehavioral ...

The European Commission granted conditional marketing authorization for Ezmekly (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients ...

The Neurofibromatosis Type 2 treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical ...

Source Reference: Chen AP, et al "Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre ...